Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Follicular 23Lymphoma, Non-Hodgkin 17Lymphoma, Mantle-Cell 16Lymphoma, Large B-Cell, Diffuse 15Lymphoma 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 8Recurrence 7Neoplasms 6Burkitt Lymphoma 5Neoplasm, Residual 3Leukemia, B-Cell 3Leukemia, Hairy Cell 2Leukemia 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mesothelioma 1Melanoma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Prolymphocytic 1

Interventions

Cyclophosphamide 8Rituximab 5fludarabine 4Vincristine 4Prednisone 4Doxorubicin 4fludarabine phosphate 3Tacrolimus 3Mycophenolic Acid 3Etoposide 3Busulfan 3venetoclax 2entrectinib 2atezolizumab 2alectinib 2acalabrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bortezomib 2trametinib 1pertuzumab 1pembrolizumab 1obinutuzumab 1liposomal doxorubicin 1isatuximab 1ibrutinib 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × obinutuzumab × 1 year × Clear all
NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University

Phase 2 Recruiting
49 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡